NMRA · Neumora Therapeutics, Inc. · Financials
$1.04
-0.10 (-8.77%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$195.41M
Shares
187.90M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$236.93M
+2.8%
FY2025
Diluted EPS
-$1.45
+5.2%
FY2025
Operating Cash Flow
-$206.44M
-12.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $153.07M | $176.07M | $200.93M | $142.72M | $91.75M | |
| $53.16M | $60.09M | $62.54M | $45.48M | $31.12M | |
| $47K | $208K | $631K | $668K | $594K | |
| $211.23M | $241.16M | $263.46M | $252.1M | $135.87M | |
| -$211.23M | -$241.16M | -$263.46M | -$252.1M | -$135.87M | |
| $4.57M | $2.01M | $0 | — | — | |
| $5.19M | $8.34M | $19.93M | — | — | |
| -$1.48M | $4.36M | $19.86M | $16.44M | $4.97M | |
| — | — | — | — | $18K | |
| -$212.72M | -$236.8M | -$243.61M | -$235.66M | -$130.9M | |
| $30K | $130K | $178K | $268K | — | |
| -$212.75M | -$236.93M | -$243.79M | -$235.93M | -$130.9M | |
| -$212.73M | -$236.99M | -$243.65M | -$235.23M | -$131.68M | |
| USD/shares | -$1.23 | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| USD/shares | -$1.23 | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| shares | — | 163.39M | 159.38M | 65.02M | 27.21M |
| shares | — | 163.39M | 159.38M | 65.02M | 27.21M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.48×
EV/EBIT
—
Peer median 8.97×
P/E (TTM)
—
Peer median 8.07×
Peer medians compare against the 310 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
45 filings
45 filers
Visit website
Investor relations